Valneva initiates rolling submission of fda biologics license application for its single-shot chikungunya vaccine candidate

Saint-herb lain (france ) , august 18 , 2 02 2 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today announces that it has initiated rolling submission of the biologics license application (bla) to the u.s. food and drug administration (fda) seeking approval of the company's single-shot chikungunya vaccine candidate in persons aged 18 years and above.
VALN Ratings Summary
VALN Quant Ranking